Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data

Show simple item record

dc.contributor.author Hemilä, Harri
dc.contributor.author Chalker, Elizabeth
dc.date.accessioned 2021-06-23T09:00:01Z
dc.date.available 2021-06-23T09:00:01Z
dc.date.issued 2021-08
dc.identifier.citation Hemilä , H & Chalker , E 2021 , ' Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data ' , Pharmacology Research & Perspectives , vol. 9 , no. 4 , 00810 . https://doi.org/10.1002/prp2.810
dc.identifier.other PURE: 165222638
dc.identifier.other PURE UUID: 73013453-4306-4eeb-a8d0-aadd5fef1538
dc.identifier.other ORCID: /0000-0002-4710-307X/work/95990621
dc.identifier.other WOS: 000683312100038
dc.identifier.uri http://hdl.handle.net/10138/331770
dc.description.abstract In this individual patient data meta-analysis we examined datasets of two randomized placebo-controlled trials which investigated the effect of nasal carrageenan separately on children and adults. In both trials, iota-carrageenan was administered nasally three times per day for 7 days for patients with the common cold and follow-up lasted for 21 days. We used Cox regression to estimate the effect of carrageenan on recovery rate. We also used quantile regression to calculate the effect of carrageenan on colds of differing lengths. Nasal carrageenan increased the recovery rate from all colds by 54% (95% CI 15%-105%; p = .003). The increase in recovery rate was 139% for coronavirus infections, 119% for influenza A infections, and 70% for rhinovirus infections. The mean duration of all colds in the placebo groups of the first four quintiles were 4.0, 6.8, 8.8, and 13.7 days, respectively. The fifth quintile contained patients with censored data. The 13.7-day colds were shortened by 3.8 days (28% reduction), and 8.8-day colds by 1.3 days (15% reduction). Carrageenan had no meaningful effect on shorter colds. In the placebo group, 21 patients had colds lasting over 20 days, compared with six patients in the carrageenan group, which corresponds to a 71% (p = .003) reduction in the risk of longer colds. Given that carrageenan has an effect on diverse virus groups, and effects at the clinical level on two old coronaviruses, it seems plausible that carrageenan may have an effect on COVID-19. Further research on nasal iota-carrageenan is warranted. en
dc.format.extent 9
dc.language.iso eng
dc.relation.ispartof Pharmacology Research & Perspectives
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 317 Pharmacy
dc.subject common cold
dc.subject iota-carrageenan
dc.subject meta-analysis
dc.subject quantile treatment effect
dc.subject randomized trial
dc.subject rhinovirus
dc.subject SARS-CoV-2
dc.subject HERPES-SIMPLEX-VIRUS
dc.subject COMMON COLD
dc.subject ANTIVIRAL ACTIVITY
dc.subject VITAMIN-C
dc.subject POLYSACCHARIDES
dc.subject LOZENGES
dc.title Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data en
dc.type Article
dc.contributor.organization Clinicum
dc.contributor.organization Biosciences
dc.contributor.organization Department of Public Health
dc.contributor.organization Harri Hemilä / Principal Investigator
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1002/prp2.810
dc.relation.issn 2052-1707
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
prp2.810.pdf 758.7Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record